期刊文献+

异丙托溴铵联合乙酰半胱氨酸治疗慢性阻塞性肺疾病稳定期临床评价 被引量:8

Clinical Evaluation on Ipratropium Bromide Combined with Acetylcysteine in the Treatment of Chronic Obstructive Pulmonary Disease at Stable Stage
下载PDF
导出
摘要 目的观察异丙托溴铵联合乙酰半胱氨酸对慢性阻塞性肺疾病(COPD)稳定期患者临床症状体征及肺功能的改善效果,以及对血清基质金属蛋白酶9(MMP-9)和转化生长因子β(TGF-β)水平的影响。方法选取医院2015年10月至2017年9月诊治的COPD稳定期患者122例,按治疗方式的不同分为观察组和对照组,各61例。两组患者均在常规对症支持治疗基础上给予乙酰半胱氨酸,观察组在此基础上联合异丙托溴铵,治疗3个月。结果治疗后,两组患者用力肺活量(FVC)、第1秒用力呼气容积(FEV_1),FEV_1/FVC及6 min步行距离(6MWD)均较治疗前上升,且观察组上升更明显(P <0. 05);血清MMP-9和TGF-β水平及临床症状体征评分均较治疗前下降,且观察组下降更明显(P <0. 05)。结论异丙托溴铵联合乙酰半胱氨酸可有效改善COPD稳定期患者的肺功能及临床症状体征,改善MMP-9及TGF-β水平,可为临床治疗COPD提供理论依据。 Objective To observe the improvement effect of ipratropium bromide combined with acetylcysteine on clinical symptoms,signs and lung function,and its effect on the levels of MMP-9 and TGF-β in patients with chronic obstructive pulmonary disease( COPD)at stable stage. Methods Totally 122 patients with COPD at stable stage treated in our hospital from October 2015 to September 2017 were selected and divided into the observation group and the control group according to different treatment methods,61 cases in each group. The two groups were given acetylcysteine on the basis of conventional symptomatic supportive treatment,on this basis,the observation group was treated with ipratropium bromide. The two groups were treated for 3 months. Results After treatment,the FVC,FEV1,FEV1/FVC and 6 MWD in the two groups were increased than those before treatment( P〈0. 05),and the increase in the observation group was more significant( P〈0. 05). The levels of serum MMP-9 and TGF-β,clinical symptoms and signs in the two groups were decreased than those before treatment( P〈0. 05),and the decrease in the observation group was more significant( P〈0. 05).Conclusion Ipratropium bromide combined with acetylcysteine in the treatment of patients with COPD at stable stage can effectively improve the lung function and clinical symptoms and signs,it can improve the levels of MMP-9 and TGF-β,which can provide a theoretical basis for the clinical treatment of COPD.
作者 兰秋艳 马义梅 加尔肯.拉斯拜 Lan Qiuyan;Ma Yimei;Jia'erken Lasibai(Department of Respiratory,The 474th Hospital of PLA,Urumqi,Xinjiang,China 83000)
出处 《中国药业》 CAS 2018年第20期55-57,共3页 China Pharmaceuticals
关键词 异丙托溴铵 乙酰半胱氨酸 慢性阻塞性肺疾病稳定期 临床疗效 肺功能 ipratropium bromide acetylcysteine chronic obstructive pulmonary disease clinical effect lung function
  • 相关文献

参考文献14

二级参考文献169

共引文献4675

同被引文献75

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部